Icosavax, Inc. — Form D
Icosavax, Inc. of Seattle, WA, a company, filed a Form D exempt-offering notice with the SEC on 2021-04-07. The offering totals $99.7M, of which $99.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-04-07
- Form: D
- Accession: 0001567619-21-007745
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $99.7M
- Amount sold: $99.7M
- Investors: 36
- Date of first sale: 2021-03-19
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-394949
Issuer
- Name: Icosavax, Inc.
- CIK: 0001786255
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 1616 Eastlake Ave. E, Ste. 208, Seattle, WA, 98102
- Phone: (858) 775-4523
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Terry A Gould | Director | Indianapolis, IN |
| Jason A Hafler | Director | Seattle, WA |
| Peter A Kolchinsky | Director | Seattle, WA |
| Mark A McDade | Director | Seattle, WA |
| Eric A Moessinger | Director | Seattle, WA |
| Adam K Simpson | Director | Seattle, WA |
| Tadataka Yamada, M.D. | Director | Seattle, WA |
| Cassia A Cearley | Executive Officer | Seattle, WA |
| Douglas A Holtzman | Executive Officer | Seattle, WA |
| Niranjan A Kanesa-thasan | Executive Officer | Seattle, WA |
| Charles A Richardson | Executive Officer | Seattle, WA |
| Adam K Simpson | Executive Officer | Seattle, WA |
Other filings by this issuer (1)
More